GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

VRCA · Mar 31, 2025

Verrica Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0000950170-25-070452General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

808.64% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-368.62% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-10.12% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

71.50% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

79.65% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-236.41% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

66.41% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

29.83% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Sep 30, 20230/8 normalizedLevel 3 Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/8 normalizedLevel 3 Jun 30, 20240/9 normalizedLevel 3 Sep 30, 20240/5 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20252/7 normalizedLevel 3 Dec 31, 20257/8 normalizedLevel 3 Mar 31, 20265/6 normalizedLevel 3 Jun 30, 20265/6 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Increased

Previous: 409.50%
Current: 808.64%
Delta: 399.13%

Cash Generation Increased

Previous: -805.27%
Current: -368.62%
Delta: 436.65%

Growth Decreased

Previous: 47.66%
Current: -10.12%
Delta: -57.77%

Inventory Pressure Increased

Previous: 32.55%
Current: 71.50%
Delta: 38.95%

Margin Increased

Previous: 65.64%
Current: 79.65%
Delta: 14.01%

Profitability Increased

Previous: -871.25%
Current: -236.41%
Delta: 634.85%

R And D Intensity Decreased

Previous: 156.49%
Current: 66.41%
Delta: -90.07%

Sbc Intensity Decreased

Previous: 94.69%
Current: 29.83%
Delta: -64.85%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · VRCA Fundamental State →Has State · Verrica Pharmaceuticals Inc. →Transitioned To · VRCA Fundamental State →Transitioned To · VRCA BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · VRCA CASH_GENERATION_INCREASED →Transitioned To · VRCA GROWTH_DECREASED →Transitioned To · VRCA INVENTORY_PRESSURE_INCREASED →Transitioned To · VRCA MARGIN_INCREASED →Transitioned To · VRCA PROFITABILITY_INCREASED →Transitioned To · VRCA R_AND_D_INTENSITY_DECREASED →Transitioned To · VRCA SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.